Determining Concentration of Neurotrophic Factors and Neuron Specific Enolase in the Blood of Newborns with Central Nervous System Damages as a New Approach in Clinical Diagnostics
The aim of the investigation is to assess the quantity of brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF) and neuron specific enolase (NSE) in plasma of newborns with perinatal hypoxic damage of CNS.
Materials and Methods. Neurotrophic factors and NSE enzyme concentrations in plasma of newborns (gestation age 31–42 weeks) was studied. The main groups consisted of newborns with the symptoms of perinatal CNS damage (group 1 — with convulsive states, group 2 — with the signs of severe perinatal CNS damage), diagnosed according to physical examination, evaluation of the neurological status dynamics and neurosonographic studies. Control group included healthy neonates. Concentration of BDNF, GDNF (R&D Systems, USA) and NSE enzyme (Vector Best, Russia) was determined by ELISA kit during hospitalization and on day 10–14 after the rehabilitation therapy.
Results. Carried out experiments revealed the significant increase of NSE concentration in plasma of newborns with convulsive states. The higher levels of this enzyme were detected in infants with severe perinatal CNS damage. Moreover, BDNF concentration significantly increases in plasma of patients with the symptoms of severe CNS damage in the period following rehabilitation therapy. These experiments also demonstrate the inverse correlation between BDNF and GDNF levels. It was shown the important prognostic value of BDNF and NSE determination in plasma of newborns with CNS injury.
Conclusion. The most diagnostic value for assessing the severity of brain damage in early neonatal period is associated with measurements of NSE and BDNF concentrations in plasma, which allows to use these markers immediately after birth and before the development of neurological symptoms.
- Tharp B.R. Neonatal seizures and syndromes. Epilepsia 2002; 43(Suppl 3): 2–10, http://dx.doi.org/10.1046/j.1528-1157.43.s.3.11.x.
- Volpe Y. Neurology of newborn. N.Y.; 2002.
- Volodin N.N., Degtyarev D.N., Khachatryan A.V., Khokhlov A.P., Navasardyants D.G. Change of neuron specific protein content — neuron specific enolase, leucine aminopeptidase, cytokine tumor necrosis factor α in infants with perinatal CNS damage. Pediatriya 1998; 5: 15–20.
- Turina O.I., Ryabukhin I.A., Rogatkin S.O., Shepeleva I.I., Degtyarev D.N., Anin A.N., Chekhonin V.P., Volodin H.H. Enzyme immunodetection of the level of gliofibrillar acid protein and antibodies against it in the assessment of perinatal CNS damages in preterm infants. Pediatriya 1995; 3: 15–19.
- Fantacci C., Capozzi D., Ferrara P., Chiaretti A. Neuroprotective role of nerve growth factor in hypoxic-ischemic brain injury. Brain Sci 2013; 3(3): 1013–1022, http://dx.doi.org/10.3390/brainsci3031013.
- Chen Y. Effects of glial cell line-derived neurotrophic factor (GDNF) on stem/progenitor cell proliferation and differentiation. Abstract of dissertation. Lexington, Kentucky; 2005.
- Airaksinen M.S., Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002; 3(5): 383–394, http://dx.doi.org/10.1038/nrn812.
- Ahmed F., Gyorgy A., Kamnaksh A., Ling G., Tong L., Parks S., Agoston D. Time-dependent changes of protein biomarker levels in the cerebrospinal fluid after blast traumatic brain injury. Electrophoresis 2012; 33(24): 3705–3711, http://dx.doi.org/10.1002/elps.201200299.
- Singh H.V., Pandey A., Shrivastava A.K., Raizada A., Singh S.K., Singh N. Prognostic value of neuron specific enolase and IL-10 in ischemic stroke and its correlation with degree of neurological deficit. Clin Chim Acta 2013; 419: 136–138, http://dx.doi.org/10.1016/j.cca.2013.02.014.
- Olenev S.N., Olenev A.S., Neronova Yu.I. Evolyutsiya mozga cheloveka [Evolution of the human brain]. Saint Petersburg: Nestor; 2000.
- Sakharnova T.A., Vedunova M.V., Mukhina I.V. Brain-derived neurotrophic factor (BDNF) and its role in the functioning of the central nervous system. Neurochemical Journal 2012; 6(4): 251–259, http://dx.doi.org/10.1134/s1819712412030129.
- Vedunova M.V., Sakharnova T.А., Mitroshina Е.V., Mukhina I.V. The role of the tropomyosin-related kinase B (TrkB) receptor in realization of neuroprotective and antihypoxic properties of brain-derived neurotrophic factor (BDNF) during normobaric hypoxia in vitro. Biomeditsinskaya radioelektronika 2014; 4: 13–14.
- Lu B. Pro-region of neurotrophins: role in synaptic modulation. Neuron 2003; 39(5): 735–738, http://dx.doi.org/10.1016/s0896-6273(03)00538-5.
- Song D.K., Choe B., Bae J.H., Park W.K., Han I.S., Ho W.K., Earm Y.E. Brain-derived neurotrophic factor rapidly potentiates synaptic transmission through NMDA, but suppresses it through non-NMDA receptors in rat hippocampal neuron. Brain Res 1998; 799(1): 176–179, http://dx.doi.org/10.1016/s0006-8993(98)00474-0.
- Tanaka T., Saito H., Matsuki N. Inhibition of GABAA synaptic responses by brain-derived neurotrophic factor (BDNF) in rat hippocampus. J Neurosci 1997; 17(9): 2959–2966.
- Porcher C., Hatchett C., Longbottom R.E., McAinch K., Sihra T.S., Moss S.J., Thomson A.M., Jovanovic J.N. Positive feedback regulation between gamma-aminobutyric acid type A (GABAA) receptor signaling and brain-derived neurotrophic factor (BDNF) release in developing neurons. J Biol Chem 2011; 286(24): 21667–21677, http://dx.doi.org/10.1074/jbc.m110.201582.
- Lebedeva O.S., Lagar’kova M.A., Kiselev S.L., Mukhina I.V., Vedunova M.V., Usova O.V., Stavrovskaya A.V., Yamshchikova N.G., Fedotova E.Y., Grivennikov I.A., Khaspekov L.G., Illarioshkin S.N. The morphofunctional properties of induced pluripotent stem cells derived from human skin fibroblasts and differentiated to dopaminergic neurons. Neurochemical Journal 2013; 7(3): 207–214, http://dx.doi.org/10.1134/s1819712413030082.
